News Headlines
-
Proteologix, Inc. To Be Acquired By Johnson & Johnson
5/16/2024
Proteologix, Inc., a privately-held biotechnology company focused on bispecific antibodies for immune-mediated diseases, today announced that it has entered into a definitive agreement to be acquired by Johnson & Johnson for $850 million in cash, with potential for an additional milestone payment.
-
Aulos Bioscience Enters Into Clinical Trial Collaboration And Supply Agreement With Merck KGaA, Darmstadt, Germany To Study Combination Of Bavencio With AU-007
5/15/2024
Aulos Bioscience, an immuno-oncology company working to revolutionize cancer care through the development of potentially best-in-class IL-2 therapeutics, today announced a new collaboration and supply agreement with Ares Trading S.A., a Swiss subsidiary of Merck KGaA, Darmstadt, Germany, for use of Bavencio (avelumab) in a clinical study of its lead human monoclonal antibody candidate, AU-007.
-
Galapagos And Blood Centers Of America Announce Strategic Collaboration To Accelerate Galapagos’ Decentralized CAR-T Manufacturing Network In The U.S.
5/15/2024
Galapagos NV and Blood Centers of America (BCA) today announced that they have entered into a strategic collaboration for the decentralized manufacturing of Galapagos’ CAR-T cell therapies through BCA’s network in the U.S.
-
Renaissance Lakewood, LLC Opens New Headquarters Global CDMO Makes Additional Investment In Ocean County, NJ Campus
5/14/2024
Renaissance Lakewood, LLC, a leading pharmaceutical contract development and manufacturing organization (CDMO), today announced the official opening of their new headquarters at 1215 Paco Way in Lakewood, NJ.
-
Efficient Processes In The Pharmaceutical Industry: Körber Simplifies The Integration Of PAS-X MES With Syntegon Packaging Systems
5/14/2024
The international technology group Körber has certified Syntegon, a global manufacturer of pharmaceutical process and packaging technology, as “PAS-X MSI Plug & Produce Ready”.
-
GenScript Biotech Corporation Announces Self-Amplifying RNA Synthesis Service For Advanced Therapeutic Applications
5/13/2024
GenScript Biotech Corporation, a global leader in life science research tools and services, has today announced the expansion of its in vitro transcription (IVT) RNA synthesis portfolio to include self-amplifying RNA (saRNA).
-
Fulcrum Therapeutics Enters Into A Collaboration And License Agreement With Sanofi For The Development And Commercialization Of Losmapimod In Facioscapulohumeral Muscular Dystrophy
5/13/2024
Fulcrum Therapeutics, Inc.® (Fulcrum) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that it has entered into a collaboration and license agreement with Sanofi (Nasdaq: SNY) for the development and commercialization of losmapimod, an oral small molecule being investigated for the treatment of facioscapulohumeral muscular dystrophy (FSHD).
-
AbbVie And Gilgamesh Pharmaceuticals Announce Collaboration And Option-To-License Agreement To Develop Next-Generation Therapies For Psychiatric Disorders
5/13/2024
AbbVie (NYSE: ABBV) and Gilgamesh Pharmaceuticals today announced a collaboration and option-to-license agreement to develop next-generation therapies for psychiatric disorders. This collaboration will leverage AbbVie's expertise in psychiatry and Gilgamesh's innovative research platform to discover novel neuroplastogens.
-
TriLink BioTechnologies Collaborates With Johns Hopkins University To Establish A New RNA Innovation Center
5/13/2024
TriLink BioTechnologies (TriLink), a Maravai LifeSciences company and global provider of life science reagents and services, is collaborating with the Johns Hopkins University to accelerate transformational research in RNA therapeutics and discovery.
-
Aldevron Announces Strategic Partnership With Acuitas Therapeutics
5/13/2024
Aldevron, a leading global manufacturer of DNA, RNA, and proteins used in cell and gene therapies and vaccine development, today announced it has entered a strategic partnership with Acuitas Therapeutics, Inc., a private biotechnology company specializing in the development of delivery systems for nucleic acid therapeutics based on lipid nanoparticles (LNPs).